Atea Pharmaceuticals (AVIR) Cash from Financing Activities (2020 - 2026)
Atea Pharmaceuticals' (AVIR) quarterly Cash from Financing Activities came in at $257000.0 in Q1 2026, up 174.06% year-on-year from $93773.9 in Q1 2025, and up 102.27% quarter-over-quarter from -$11.3 million in Q3 2025.
Atea Pharmaceuticals (AVIR) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Atea Pharmaceuticals' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $257000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 174.06% year-over-year to $257000.0 in Q1 2026; TTM through Mar 2026 was -$25.1 million, a 10830.87% decrease from a year earlier, with the FY2025 full-year figure at -$25.7 million, down 9742.32% from the prior year.
- Cash from Financing Activities advanced to $257000.0 in Q1 2026 per AVIR's latest filing, from -$11.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $257000.0 in Q1 2026 and bottomed at -$14.1 million in Q2 2025.
- The 5-year median for Cash from Financing Activities is $132000.0 (2022), against an average of -$2.5 million.
- Across the five-year window, Cash from Financing Activities plunged 9762.39% in 2025 and soared 174.06% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at $147000.0 in 2022, then tumbled by 37.41% to $92000.0 in 2023, then rose by 27.17% to $117000.0 in 2024, then plunged by 9762.39% to -$11.3 million in 2025, then jumped by 102.27% to $257000.0 in 2026.
- Per Business Quant, the three latest AVIR Cash from Financing Activities figures stand at $257000.0 (Q1 2026), -$11.3 million (Q3 2025), and -$14.1 million (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Atea Pharmaceuticals | 376.19 Mn | 376.19 Mn | - | 257,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 257,000.00 |
| Mar 31, 2026 | 257,000.00 |
| Sep 30, 2025 | -11.31 Mn |
| Sep 30, 2025 | -11.31 Mn |
| Jun 30, 2025 | -14.09 Mn |
| Jun 30, 2025 | -14.09 Mn |
| Mar 31, 2025 | -347,000.00 |
| Mar 31, 2025 | -347,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Mar 31, 2024 | 150,000.00 |
| Mar 31, 2024 | 150,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Mar 31, 2023 | 165,000.00 |
| Mar 31, 2023 | 165,000.00 |
| Sep 30, 2022 | 147,000.00 |
| Sep 30, 2022 | 147,000.00 |
| Mar 31, 2022 | 223,000.00 |
| Mar 31, 2022 | 223,000.00 |